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This study aims to detect and clarify signals of serious skin reactions associated with 
benzodiazepine anticonvulsant therapy in the FDA Adverse Event Reporting System 
(FAERS). Methods: Cases reported to FAERS between 1997 and 2012 were retrieved. 
The MedDRA Preferred Terms were used to define serious skin reactions. Individual 
anticonvulsant benzodiazepines were identified by generic names. Empirical Bayes 
Geometric Mean (EBGM) with 95% confidence interval (EB05-EB95) were calculated 
as disproportionality measures. Drug-event combinations with EB05≥ 2 were con-
sidered signals that warrant further review. Results: 4,411 reports of serious skin 
reactions were submitted for all anticonvulsant agents. 6.3% were for benzodiaz-
epines (279), corresponding to: clobazam (33), clonazepam (54), clorazepate (41), 
diazepam (82), and lorazepam (69). Signals were detected for clorazepate (EBGM 9.6 
EB05-EB95 7.4-12.4) and clobazam (EBGM 8.7 EB05-EB95 6.4-11.5). Disproportional 
reporting was found for other benzodiazepines, albeit didn’t reach signal threshold: 
diazepam (EBGM 2.3 EB05-EB95 1.9-2.8), lorazepam (EBGM 2.2 EB05-EB95 1.8-2.7), and 
clonazepam (EBGM 1.5 EB05-EB95 1.2-1.9). Eighty one (29%) reported serious skin 
events were fatal, corresponding to: clobazam (7), clonazepam (12), clorazepate (16), 
diazepam (30), and lorazepam (16). Most of reported events listed patient exposure 
to ≥ 2 concomitant drugs at event occurrence time. ConClusions: Anticonvulsant 
therapy with benzodiazepines, particularly clobazam and clorazepate, might be 
associated with serious skin reactions. In concordance with FDA’s recommenda-
tion, patients should seek immediate help when dermal signs and symptoms are 
appeared and alternative anticonvulsant agent should be considered by prescribers. 
Signal evaluation activities are required to further characterize this risk.
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objeCtives: This retrospective study examined the temporal relationship of diag-
nosis, treatment, health care utilization, and clinical outcomes in patients with 
Tuberous Sclerosis (TSC)-related renal angiomyolipoma in the US. Methods: 
Patients with ≥ 1 diagnosis of TSC (ICD-9-CM 759.5) and angiomyolipoma (ICD-9-CM 
223.0 and other codes) were extracted from the MarketScan® Commercial Database 
1/1/2000 - 3/31/2013. Patients were followed from the first diagnosis of TSC or angio-
myolipoma (index date) until inpatient death or end of study follow-up. During the 
follow-up, proportion of patients with each event and days from index date to event 
(among those with the event) were reported. An innovative graph was explored to 
describe the natural history of events in this population. Results: The final sample 
consisted of 605 patients (mean age 26.8): 225 patients age< 18 (mean age 9.8, 55% 
female, median follow-up 3.4 years) and 380 patients age≥ 18 (mean age 36.9, 73% 
female, median follow-up 2.2 years). In patients < 18, 87% had TSC diagnosis before 
angiomyolipoma (angiomyolipoma was diagnosed 25.7 months after TSC on aver-
age), 2.8% had complete nephrectomy (8.5 months after index date); emergency 
room (ER) visit, 61% (16.6 months); inpatient admission, 48% (17.0 months); chronic 
kidney disease (CKD), 12% (32.3 months); embolization, 11% (36.2 months); end 
stage renal disease (ESRD), 1.3% (40.9 months); and 1.4% partial nephrectomy (42.0 
months). In patients ≥ 18, 56% had TSC diagnosis before angiomyolipoma (angiomy-
olipoma was diagnosed 16.9 months after TSC), ER visit, 56% (9.9 months); inpatient 
admission, 50% (11.3 months); partial nephrectomy, 7.9% (11.9 months); complete 
nephrectomy, 11.4% (13.9 months); CKD, 23% (15.1 months); embolization, 19% (17.1 
months); and ESRD, 5.3% (20.1 months). ConClusions: This study suggested that 
time from a TSC diagnosis to an angiomyolipoma diagnosis was long and sometimes 
was preceded with ER visits, hospitalizations and surgeries. The innovative graphing 
of natural history can help raise disease awareness in TSC.
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objeCtives: To assess real-world effectiveness, based on registry data, of natali-
zumab in multiple sclerosis (MS) patients with highly active relapsing-remitting MS 
(RRMS). Methods: Phase IV, observational, retrospective, multi-center database 
analysis on data from the period January 2009 – January 2013. Statistical analy-
ses were performed using Kaplan-Meier and Cox PH regression. Inclusion criteria 
comprised adults aged ≥ 18 with high disease activity with rapidly evolving severe 
RRMS or a relapse despite treatment with beta-interferon or glatiramer acetate. The 
main outcome measure was change from annualized baseline relapse rate (ARR), 
with secondary endpoints comprising sustained disability progression and improve-
ment at 12/24 months, and change in the mean Expanded Disability Status Scale 
(EDSS). Change from baseline ARR comprised ARR absolute values, relative reduc-
tion (percentage), and percentage of patients remaining relapse-free. Analyses were 
presented using frequency tables, crosstabs, graphics and, for EDSS survival analysis 
was conducted. Subgroup analyses were conducted for age, gender and prior treat-
ment received. Results: A total of 216 individuals (72% of whom females) were 
included in the study. Mean age at onset of MS was 27 years, 29 years at diagnosis, 
38 years at start of natalizumab therapy. A significant decrease in mean ARR was 
seen after 12 months compared to baseline (N= 216; Δ = 0.76; p-value< 0.001), and 
between the first and second years of treatment (N= 208; Δ = 0.06; p-value= 0.030). 
There was no significant variation across subgroups. Mean EDSS changed from 3.26 
at baseline to 3.02 at 12 months and 3.16 at 24 months. No new safety concerns 
were noted. ConClusions: Natalizumab treatment in Hungary was associated 
with two-year effectiveness as shown by reduced ARR and stabilized EDSS over the 
observation period. These results are important for decision-makers striving to 
burden of disease(n= 17). Registry-data was used in 3 studies to validate/assess 
generalizability. All modeling studies combined registry with non-registry-data (e.g. 
RCT). ConClusions: Registries provide a rich source of information on real-world 
patients which are being incorporated into health economic analyses. Although 
Nordic registry-data is being utilized in HE studies, many analyses important to HE 
are not represented. These preliminary findings suggest that HE should continue to 
broaden the use and application of registry-data in the field of rheumatic disease. 
Given the gap in data required for an economic-evaluation (e.g. modeling), research-
ers must continue to be aware of potential issues associated with the synthesis of 
RCT and registry-data.
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objeCtives: Despite the major health care impact worldwide of fragility fracture, 
there are few systems in place to identify and capture subjects after a fragility frac-
ture to ensure appropriate assessment and treatment to reduce future fracture risk 
and adverse outcomes. We implemented a multidisciplinary systematic follow-up 
of fragility fractures to close the care gap. Methods: We recruited 543 subjects 
over 40 years of age who sustained a fragility fracture at the orthopaedic clinic of 
Hôpital du Sacré-Cœur de Montréal or Hôpital Jean-Talon hospital from July 2010 
to 2013. Demographic and clinical data were assessed over 18-months of follow-up. 
We analysed data of patients who have completed at least 18 months of follow-up 
(women n= 99; men n= 16). We described demographic data, BMD, perceived compli-
ance to treatment, and subsequent fracture rates. We assessed the effect on bone 
markers and vitamin D levels using T-test. Results: Mean age was at 61 years. 
The common fracture site was the wrist (40%) followed by the ankle and proximal 
humerus (13%), vertebrae (10%) and hip (7%). Close to 41.7% of women and 20% of 
men had already sustained a previous fragility fracture. At 18 months, 10.1% of 
women and 6.3% of men had already sustained a new fracture. High CTX-1 levels 
(> 0.3 ng/mL) dropped from 46.7% to 21.4% for women and 61.5% to 23.1% for men 
after 18 months of treatment (p< 0.01). Low Vitamin D levels (< 80 nmol/L) increased 
from 63% to 87.5% for women and 16.7% to 83.3% for men (p< 0.00001). Women and 
men perceived they were still persistent and adherent to treatment at 18 months in 
90% and 88% of the time, respectively. ConClusions: Better diagnostic tools and 
systematic management of the fragility fractures and compliance monitoring can 
lower the refracture rates in the long term in this at-risk population.
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objeCtives: In 2005, a quality measure was added to the Healthcare Effectiveness 
Data and Information Set (HEDIS) that quantifies the proportion of rheumatoid 
arthritis (RA) patients who receive disease modifying anti-rheumatic drug (DMARD) 
therapy in a given year. This study describes annual trends in the HEDIS RA manage-
ment quality measure among commercially- and Medicare supplemental-insured 
U.S. RA patients from 2005 to 2012. Methods: This was a retrospective observa-
tional study based on U.S. administrative claims data. Patients selected for study 
during a given measurement year were aged ≥ 18 years, had continuous insurance 
enrollment throughout the year, and had two outpatient claims, on different days, 
with a diagnosis of RA (ICD-9-CM codes 714.0, 714.1, 714.2, 714.81). Receipt of a 
biologic or non-biologic DMARD therapy was assessed annually from 2005 to 2012. 
Bivariate statistics were used to test for differences across the years. Results: 
Annual sample sizes averaged ~95,000 RA patients. From 2005 to 2012, the RA qual-
ity measure was stable at approximately 83% of RA patients receiving DMARD 
treatment. Biologic DMARD utilization increased from 32% in 2005 to 39% in 2012 
(p< 0.001), whereas use of non-biologic DMARDs decreased slightly from 74% to 72% 
(p< 0.001). Among the subset of patients aged ≥ 65 years with Medicare Supplemental 
insurance, the RA quality measure was slightly lower at approximately 78% receiving 
DMARD therapy. Fewer RA patients with Medicare Supplemental insurance received 
biologic DMARDs, however, utilization increased from 23% in 2005 to 29% in 2012 
(p< 0.001). In the same time period, non-biologic DMARD use decreased from 73% to 
69% (p< 0.001). ConClusions: Since the 2005 introduction of the HEDIS RA man-
agement quality measure, increases in the use of biologic DMARD therapy were 
offset by decreases in the use of non-biologic DMARD therapy. Findings suggest 
potential room for improvement in the quality of care for RA patients.
Neurological DisorDers – clinical outcomes studies
PND1
comParative PHarmacovigilaNce aNalysis of beNzoDiazePiNe 
aNticoNvulsaNt tHeraPy aND serious skiN eveNts
Ali A.K.
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objeCtives: In late 2013, the FDA announced to the public that clobazam is linked 
to serious skin events, including Stevens-Johnson syndrome (SJS), toxic epidermal 
necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP), and con-
sequently approved changes to clobazam label and medication guide. However, no 
comparative pharmacovigilance analysis was conducted for other anticonvulsant 
benzodiazepines, including clonazepam, clorazepate, diazepam, and lorazepam. 
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tive pulmonary diseases, asthma, coronary artery disease, diabetes, obesity, liver, 
or thyroid condition, cancer and stroke). Ordinary least square regression (OLS) 
and multinomial logistic regressions on low (< 1.0 mg/l), average (1-3 mg/l) and 
high (> 3 mg/l) were used to analyze the association between antidepressant use 
and CRP. Results: Antidepressant use was reported by 13% of the adults and the 
average CRP value for the sample was 4.85 mg/l (SE = 0.0113). 22% had low CRP, 
33% had average CRP and 45% had high CRP values. Average CRP values were not 
statistically different between antidepressant users and non-users. Other factors 
that were significantly associated with CRP were: perceived health status, smok-
ing and income. For example, adults with excellent perceived health status had 
significantly lower CRP values (p < 0.004) as compared to those with poor health 
status. ConClusions: In this population-based study, no statistically significant 
association between antidepressant use and inflammatory bio-markers were found 
in individuals with an inflammatory condition. Future research may need to focus 
on specific inflammatory conditions including depression.
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objeCtives: To estimate the annual aggregate expenditures of prescription phar-
maceuticals in the treatment of peripheral neuropathic pain in the United States 
over a seven year period. Methods: We utilized annually compiled data for the 
years 2005-2011 of the Medical Expenditure Panel Survey (MEPS), a publically avail-
able dataset to construct cross-sectional, representative estimates of medical 
expenses and utilization for the civilian, non-institutionalized US population. We 
identified cases using International Classification of Disease-Ninth Revision, Clinical 
Modification (ICD-9-CM) codes which denoted conditions prone to peripheral neu-
ropathy (diabetes mellitus and herpes zoster), or indicated peripheral neuropathy 
directly. These were associated with pharmacy records using Cerner Multum™ clas-
sifications for classes of medication commonly used for treating neuropathic pain. 
Prescriptions counts and costs were aggregated by year. Survey weighting, clustering 
and stratification variables were used to give unbiased national estimates of pre-
scription utilization and expenditures. All costs were inflated to 2011 dollars using 
the medical Consumer Price Index. Results: A total of 2782 survey respondents 
had at least one prescribed medicine associated with treatment of a neuropathic 
pain diagnosis, representing 2.9 million persons in 2005 and increasing to 3.9 million 
in 2011 (annual increase of 3.1%, p= 0.05). Both total prescriptions and total expendi-
tures peaked in 2008 ($1.1 billion(b) and 20.3 million (m) prescriptions, respectively), 
then declined through 2011. Narcotic analgesics and gabapentinoids were the drug 
classes with the largest mean annual expenditures ($305m and $211m) , followed by 
serotonin-noradrenalin reuptake inhibitors ($141m). Non-gabapentinoid anticon-
vulsants, tricyclic antidepressants, and topical analgesics had substantial declines 
in usage and expenditures from 2005 to 2011. Non-narcotic analgesics utilization 
and expenses, including NSAIDs and tramadol, remained largely stable during the 
study period. ConClusions: Prescription medications for peripheral neuropathic 
pain treatment experienced large swings in usage and expenditures from 2005-
2011, peaking in 2008 despite steady increases in the number of neuropathic pain 
medication users.
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objeCtives: This study examined patient age and gender as well as racial and 
geographic variations in the prevalence of cystic fibrosis (CF), a chronic lung 
disease common in children and young adults, in the U.S. Medicaid popula-
tion. Methods: A retrospective study was performed among the U.S. Medicaid 
fee-for-service (FFS) population from 2008 through 2009. CF patients were 
identified using International Classification of Disease, 9th Revision, Clinical 
Modification (ICD-9-CM) diagnosis code 277.0x. Patients with continuous Medicaid 
FFS enrollment in both 2008 and 2009 were included for analysis. Any managed 
care enrollment during the period was not permitted. CF prevalence was stratified 
by region, state, age, gender and race, for all patients and measured by number and 
percentage, in each category. Results: A total of 2,550 patients were diagnosed 
with CF among the Medicaid FFS population in 2008 and 2009. Prevalence was the 
highest (0.15%) for patients under age 40 years, followed by patients age 40 to 59 
(0.03%), and 60+ (0.01%). CF prevalence by race was also examined, with the follow-
ing results: White (0.06%), Hispanic (0.04%), Black (0.03%), Native American (0.02%) 
and Asian (0.02%). Male patients had a relatively higher prevalence compared to 
female patients (0.06% vs. 0.05%). Geographic variation was also analyzed, and 
the highest CF prevalence was observed in Minnesota (0.16%), followed by Ohio, 
Maryland, North Dakota (all at 0.11%) and West Virginia (0.09%). Patients residing 
in the Midwest had the highest prevalence rate (0.07%), compared to the Northeast 
(0.05%), South (0.04%) and West (0.03%). ConClusions: Statistical evidence shows 
that younger patients have a higher probability of being diagnosed with CF, with 
white patients more likely to be diagnosed with CF compared to those of other 
races. Male patients who resided in the Midwest U.S. region were also found to be 
at higher risk for a CF diagnosis.
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optimize spending on MS treatments and for clinical experts looking for improved 
understanding of the therapeutic benefits of natalizumab.
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objeCtives: This research was conducted to provide a systematic pairwise com-
parison of all available botulinum toxin type A treatments for cervical dystonia 
(CD) as there is a lack of direct head to head clinical trial data evidence. Three 
botulinum toxin type A products have been approved by the FDA for managing CD: 
AbobotulinumtoxinA, OnabotulinumtoxinA and IncobotulinumtoxinA. A pair-wise 
efficacy comparison was performed for all three toxins based on literature-reported 
clinical outcomes. Methods: Multi-armed randomized controlled trials (RCTs) for 
inclusion were identified using a systematic literature review. RCTs were assessed 
for comparability based on patient population and comparable efficacy outcome 
measures. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total 
score was selected as the efficacy outcome measurement for assessment. A mixed 
treatment comparison (MTC) was conducted using a Bayesian hierarchical model 
allowing indirect comparison of the efficacies of the interventions. Results: The 
network of six RCTs with fourteen arms formed a linear series of “steps” which 
facilitated the comparison of all botulinum toxin type A treatments of interest. 
Due to the limitation of available clinical data, this study only investigated the 
main effect of toxin treatments without explicitly considering potential confound-
ing factors such as gender and formulation differences. There was reasonable 
agreement between the number of unconstrained data points, residual deviance 
and pair-wise results, suggesting a coherent network. The results for TWSTRS 
total scale change from baseline for all treatments were: Placebo (mean -4.487, 
SE 1.402), AbobotulinumtoxinA (mean -11.08, SE 1.41), OnabotulinumtoxinA (mean 
-11.77, SE 1.44) and IncobotulinumtoxinA (mean -12.38, SE 1.79); where a negative 
number indicates symptom improvement. ConClusions: This research suggests 
that all botulinum toxin type A treatments were effective compared to placebo 
in cervical dystonia. However, based on this MTC analysis, there is no significant 
efficacy difference between AbobotulinumtoxinA, OnabotulinumtoxinA and 
IncobotulinumtoxinA.
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objeCtives: The understanding of the clinical meaningfulness of outcomes in 
schizophrenia is important to determine the value of new treatments for patients, 
caregivers, practitioners and payers. The aim of this research was to provide an 
overview of general concepts and methodologies applied to determine meaningful-
ness of endpoints, to describe how outcomes are measured in schizophrenia and 
how treatment success and clinical meaningfulness are defined in schizophrenia 
from a Health Technology Assessment (HTA) perspective. Methods: We conducted 
a targeted literature search focusing on antipsychotic treatment and clinical mean-
ingfulness of schizophrenia outcomes, a review of HTA submission guidelines, HTA 
reports in schizophrenia, a survey on individual country requirements in sixteen 
countries and an analogue analysis to identify payer definitions of clinical meaning-
ful differences. Results: No consistent approach exists from payers, or in the liter-
ature, to determine clinical meaningfulness in schizophrenia outcomes. Historically, 
payers have based their value assessments of antipsychotics on available clinical 
evidence using systematic literature reviews and meta-analyses. Most widely used 
efficacy endpoints in antipsychotic trials are changes in PANSS scores, BPRS and CGI 
(CGI-I and/or CGI-S). Payers noted considerable variation in the definition of clini-
cal meaningfulness to determine treatment response (20%-60% change in PANSS 
or BPRS score from baseline). Payers recommend validity should be demonstrated 
for clinical relevance of change on these endpoints using anchors such as patient-
reported, functional and global outcomes. Overall, payers suggest establishing a 
minimal clinically important difference (MCID) based on robust scientific criteria. 
Beyond the traditional clinical measures, payers would like to see complementary 
evidence on quality of life, patient satisfaction, family burden, resource utilization 
and hospitalization. ConClusions: Approaches to determine clinical meaningful-
ness in schizophrenia outcomes vary widely. Further research is needed to validate 
the meaningfulness of changes in commonly used clinical endpoints and generate 
additional payer relevant evidence on patient and caregiver burden.
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objeCtives: To examine the association between antidepressant drug use and C 
– Reactive Protein (CRP) among adults with inflammatory medical conditions after 
controlling for gender, race, age, income, Non-steroidal anti-inflammatory drug use, 
smoking, perceived health status, alcohol use and physical activity. Methods: 
Retrospective cross-sectional study with linked data from laboratory, prescription 
medication, medical conditions and demographic files of the National Health and 
Nutritional examination Survey (NHANES). The study sample (N = 3,492) consisted of 
adults (≥ 20 years) with any inflammatory condition (arthritis, gout, chronic obstruc-
